Key statistics dashboard for Protagonist Therapeutics, Inc. (PTGX). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders.
Stock Data
| Price | $142.84 |
| Market Cap | $9.2B |
| Beta | 2.11 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | 117.93 |
| Price / Book | 11.25 |
| P/S | 32.76 |
| P/FCF | 69.89 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 99.86% |
| EBIT Margin | 29.91% |
| EBITDA Margin | 30.31% |
| Operating Margin | 20.69% |
| Net Margin | 29.40% |
Financial Health
| Current Ratio | 21.71 |
| Quick Ratio | 21.71 |
| Cash Ratio | 11.30 |
| Debt / Equity | 0.01 |
| Debt / Assets | 1.04% |
| Interest Coverage | 0.00 |
| Piotroski F-Score | 3 |
| Altman Z-Score | 59.63 |
Per-Share Data
| Revenue per share | 4.28 |
| Book Value per share | 12.76 |
| Cash per share | 11.87 |
| FCF per share | 2.00 |
| Tangible Book Value per share | 12.76 |
| Dividend per share | 0.00 |
Related companies: ACLX · AKRO · ALKS · CRNX · IMVT · KYMR · NAMS
Explore sector: Healthcare · Biotechnology
More sections of PTGX: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks